Biohaven Ltd. (BHVN) stock
Close on Nov 13, 2026Market cap $2.09BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $2.09B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -22.67%
Fundamentals
- Net income
- -$542.68M
- EPS, diluted
- -$3.86
- Free cash flow
- -$473.17M
- Book value per share
- -$0.65
- Diluted shares
- 151M
Trading
- Next earnings
- Mar 1, 2027 (estimated, after the close)
- Previous close
- $14.07
- Open
- $14.29
- Day's range
- $13.37 – $14.29
- Volume
- 1,257,764
- Average volume (20 days)
- 3,815,790
- Beta (5 years)
- 1.60
- 52-week range
- $7.78 – $18.24
- RSI (14 days)
- 47.8
- Volatility (1 year)
- 82.8%
- Relative volume
- 0.44×
- WACC
- 12.2%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | BHVN | S&P 500 | Difference | BHVN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +21.0% | -3.0% | +24.1 pts | ||
| 3 months | -6.9% | -2.8% | −4.2 pts | ||
| Year to date | +22.4% | +11.5% | +10.9 pts | ||
| 1 year | +71.0% | +13.5% | +57.6 pts | ||
| 3 years | -52.0% | +77.7% | −129.7 pts | -21.7% | +21.1% |
| 5 years | -88.7% | +72.6% | −161.3 pts | -35.3% | +11.5% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Biohaven filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- Update
About Biohaven
Pharmaceutical Preparations
Biohaven is a biopharmaceutical company that discovers, develops, and commercializes therapies for neurological, immunological, and metabolic conditions. The company advances several clinical-stage drug candidates across multiple therapeutic platforms. Key investigational assets include BHV-1300 and BHV-1400, which are extracellular protein degraders under development for autoimmune diseases such as Graves' disease and IgA nephropathy. It also develops opakalim, a potassium channel activator for epilepsy, and taldefgrobep alfa, an investigational agent targeting obesity and neuromuscular disorders. Biohaven's potential treatments are designed for patients affected by serious central nervous system, autoimmune, and metabolic disorders.
Company profile, executives and historyBiohaven stock: common questions
What is Biohaven's stock price?
BHVN closed at $13.82 on Nov 13, 2026, down 1.78% on the day. Over the past 52 weeks it traded between $7.78 and $18.24.
What is Biohaven's market cap?
Biohaven was worth $2.09B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is BHVN's P/E ratio?
Biohaven lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.86), so it has no meaningful P/E ratio.
Does Biohaven pay a dividend?
No. Biohaven has not paid a cash dividend over the last twelve months.
When does Biohaven report earnings next?
Biohaven is expected to report Q4 FY2026 results on Mar 1, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has BHVN stock performed over the past year?
Including dividends, BHVN returned +71.0% over the past year, against +13.5% for the S&P 500.
How many BHVN shares are sold short?
15M shares were sold short at the latest FINRA report, 11.54% of the float, or 2.9 days of average trading volume.
Who are Biohaven's competitors?
Companies most similar to Biohaven by business, industry and size include XENE, OVID, ANRO, PRAX, ANVS.
See a number that looks wrong?